Skip to content
2000
image of Epithelial to Mesenchymal Transition as a Therapeutic Target for MicroRNAs in Triple Negative Breast Cancer

Abstract

Breast Cancer (BC) is one of the leading causes of cancer-related deaths among females. Due to its broad heterogeneity, BC can be categorized into many subtypes, with Triple Negative Breast Cancer (TNBC) as the most aggressive one. TNBC, in addition to its unique pathophysiological features, is also characterized by specific molecular events. It is well-documented that the pathogenesis of TNBC is at least partially promoted by the process of Epithelial-to-Mesenchymal Transition (EMT). The development of EMT-associated drug resistance and metastases in TNBC patients despite chemotherapeutic treatment highlights the urgent need for the development of new treatment options. Therapeutic delivery of specific anti-tumor microRNAs is considered a promising approach for treating various forms of cancer. Analysis of the current literature suggests that EMT-suppressing microRNAs may represent a novel therapeutic treatment of breast cancer. The systemic delivery of microRNAs miR-34, miR-200, and miR-425, which specifically target the molecular drivers of EMT, showed great promise in treating TNBC in preclinical studies. However, the low specificity of systemic delivery of microRNAs , high levels of microRNA diffusion from liposomes, and high nonspecific toxicity dampen enthusiasm for the immediate use of this therapeutic approach in the clinic. This review examines the molecular mechanisms of EMT-induced drug resistance in TNBC and highlights new advances in the development of microRNA-based molecular therapy. Lastly, possible ways to overcome these shortcomings are also discussed.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673382509250801061216
2026-02-23
2026-03-02

  • From This Site

    /content/journals/cmc/10.2174/0109298673382509250801061216
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021 71 3 209 249 10.3322/caac.21660 33538338
    [Google Scholar]
  2. Badve S. Dabbs D.J. Schnitt S.J. Baehner F.L. Decker T. Eusebi V. Fox S.B. Ichihara S. Jacquemier J. Lakhani S.R. Palacios J. Rakha E.A. Richardson A.L. Schmitt F.C. Tan P.H. Tse G.M. Weigelt B. Ellis I.O. Reis-Filho J.S. Basal-like and triple-negative breast cancers: A critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 2011 24 2 157 167 10.1038/modpathol.2010.200 21076464
    [Google Scholar]
  3. Perou C.M. Sørlie T. Eisen M.B. van de Rijn M. Jeffrey S.S. Rees C.A. Pollack J.R. Ross D.T. Johnsen H. Akslen L.A. Fluge Ø. Pergamenschikov A. Williams C. Zhu S.X. Lønning P.E. Børresen-Dale A.L. Brown P.O. Botstein D. Molecular portraits of human breast tumours. Nature 2000 406 6797 747 752 10.1038/35021093 10963602
    [Google Scholar]
  4. Amin M.B. The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin 2017 67 2 93 99 Mar 10.3322/caac.21388 28094848
    [Google Scholar]
  5. Cserni G. Chmielik E. Cserni B. Tot T. The new TNM-based staging of breast cancer. Virchows Arch 2018 472 5 697 703 10.1007/s00428‑018‑2301‑9 29380126
    [Google Scholar]
  6. Cserni G. Histological type and typing of breast carcinomas and the WHO classification changes over time. Pathologica 2020 112 1 25 41 10.32074/1591‑951X‑1‑20 32202537
    [Google Scholar]
  7. Breast Tumours: WHO classification of tumours (Medicine), 5th ed.; 2019, 2.
    [Google Scholar]
  8. Takahashi H. Oshi M. Asaoka M. Yan L. Endo I. Takabe K. Molecular biological features of Nottingham histological Grade 3 breast cancers. Ann Surg Oncol 2020 27 11 4475 4485 10.1245/s10434‑020‑08608‑1 32436191
    [Google Scholar]
  9. Davies C. Godwin J. Gray R. Clarke M. Cutter D. Darby S. McGale P. Pan H.C. Taylor C. Wang Y.C. Dowsett M. Ingle J. Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 2011 378 9793 771 784 10.1016/S0140‑6736(11)60993‑8 21802721
    [Google Scholar]
  10. Hammond M.E.H. Hayes D.F. Dowsett M. Allred D.C. Hagerty K.L. Badve S. Fitzgibbons P.L. Francis G. Goldstein N.S. Hayes M. Hicks D.G. Lester S. Love R. Mangu P.B. McShane L. Miller K. Osborne C.K. Paik S. Perlmutter J. Rhodes A. Sasano H. Schwartz J.N. Sweep F.C.G. Taube S. Torlakovic E.E. Valenstein P. Viale G. Visscher D. Wheeler T. Williams R.B. Wittliff J.L. Wolff A.C. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010 134 7 e48 e72 10.5858/134.7.e48 20586616
    [Google Scholar]
  11. Krishnamurti U. Silverman J.F. HER2 in breast cancer: A review and update. Adv Anat Pathol 2014 21 2 100 107 10.1097/PAP.0000000000000015 24508693
    [Google Scholar]
  12. Slamon D.J. Clark G.M. Wong S.G. Levin W.J. Ullrich A. McGuire W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 235 4785 177 182 10.1126/science.3798106 3798106
    [Google Scholar]
  13. Wolff A.C. Hammond M.E.H. Allison K.H. Harvey B.E. Mangu P.B. Bartlett J.M.S. Bilous M. Ellis I.O. Fitzgibbons P. Hanna W. Jenkins R.B. Press M.F. Spears P.A. Vance G.H. Viale G. McShane L.M. Dowsett M. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. J. Clin. Oncol 2018 36 20 2105 2122 10.1200/JCO.2018.77.8738 29846122
    [Google Scholar]
  14. Bauer K.R. Brown M. Cress R.D. Parise C.A. Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer 2007 109 9 1721 1728 10.1002/cncr.22618 17387718
    [Google Scholar]
  15. Morris G.J. Naidu S. Topham A.K. Guiles F. Xu Y. McCue P. Schwartz G.F. Park P.K. Rosenberg A.L. Brill K. Mitchell E.P. Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients. Cancer 2007 110 4 876 884 10.1002/cncr.22836 17620276
    [Google Scholar]
  16. Tibshirani R. Hastie T. Narasimhan B. Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. USA 2002 99 10 6567 6572 10.1073/pnas.082099299 12011421
    [Google Scholar]
  17. Pu M. Messer K. Davies S.R. Vickery T.L. Pittman E. Parker B.A. Ellis M.J. Flatt S.W. Marinac C.R. Nelson S.H. Mardis E.R. Pierce J.P. Natarajan L. Research-based PAM50 signature and long-term breast cancer survival. Breast Cancer Res Treat 2020 179 1 197 206 10.1007/s10549‑019‑05446‑y 31542876
    [Google Scholar]
  18. Parker J.S. Mullins M. Cheang M.C.U. Leung S. Voduc D. Vickery T. Davies S. Fauron C. He X. Hu Z. Quackenbush J.F. Stijleman I.J. Palazzo J. Marron J.S. Nobel A.B. Mardis E. Nielsen T.O. Ellis M.J. Perou C.M. Bernard P.S. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol 2009 27 8 1160 1167 10.1200/JCO.2008.18.1370 19204204
    [Google Scholar]
  19. Lehmann B.D. Bauer J.A. Chen X. Sanders M.E. Chakravarthy A.B. Shyr Y. Pietenpol J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest 2011 121 7 2750 2767 10.1172/JCI45014 21633166
    [Google Scholar]
  20. Lehmann B.D. Jovanović B. Chen X. Estrada M.V. Johnson K.N. Shyr Y. Moses H.L. Sanders M.E. Pietenpol J.A. Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection. PLoS One 2016 11 6 e0157368 10.1371/journal.pone.0157368 27310713
    [Google Scholar]
  21. Burstein M.D. Tsimelzon A. Poage G.M. Covington K.R. Contreras A. Fuqua S.A.W. Savage M.I. Osborne C.K. Hilsenbeck S.G. Chang J.C. Mills G.B. Lau C.C. Brown P.H. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin. Cancer Res 2015 21 7 1688 1698 10.1158/1078‑0432.CCR‑14‑0432 25208879
    [Google Scholar]
  22. Błaszczak E. Miziak P. Odrzywolski A. Baran M. Gumbarewicz E. Stepulak A. Triple-negative breast cancer progression and drug resistance in the context of epithelial–mesenchymal transition. Cancers 2025 17 2 228 10.3390/cancers17020228 39858010
    [Google Scholar]
  23. Haerinck J. Goossens S. Berx G. The epithelial–mesenchymal plasticity landscape: principles of design and mechanisms of regulation. Nat. Rev. Genet 2023 24 9 590 609 10.1038/s41576‑023‑00601‑0 37169858
    [Google Scholar]
  24. Parfenyev S.E. Shabelnikov S.V. Pozdnyakov D.Y. Gnedina O.O. Adonin L.S. Barlev N.A. Mittenberg A.G. Proteomic analysis of Zeb1 interactome in breast carcinoma cells. Molecules 2021 26 11 3143 10.3390/molecules26113143 34074001
    [Google Scholar]
  25. Bangay G. Isca V.M.S. Brauning F.Z. Dinić J. Pešić M. Palma B.B. dos Santos D.J.V.A. Díaz-Lanza A.M. de Melo E.B. Martins J.P.A. Rijo P. Exploring SAR insights into royleanones for P-gp modulation. Biomed Pharmacother 2025 185 117943 10.1016/j.biopha.2025.117943 40024056
    [Google Scholar]
  26. Al-Saeedi F. Rajendran P. Anti-metastasis activity of 5,4′-dihydroxy 6,8-dimethoxy 7-O-rhamnosyl flavone from Indigofera aspalathoides Vahl on breast cancer cells. Sci. Rep 2024 14 1 12349 10.1038/s41598‑024‑63136‑2 38811791
    [Google Scholar]
  27. Grzegrzolka J. Biala M. Wojtyra P. Kobierzycki C. Olbromski M. Gomulkiewicz A. Piotrowska A. Rys J. Podhorska-Okolow M. Dziegiel P. Expression of EMT markers SLUG and TWIST in breast cancer. Anticancer Res 2015 35 7 3961 3968 26124343
    [Google Scholar]
  28. Nedeljković M. Vuletić A. Mirjačić Martinović K. Divide and conquer—targeted therapy for triple-negative breast cancer. Int. J. Mol. Sci 2025 26 4 1396 10.3390/ijms26041396 40003864
    [Google Scholar]
  29. Acheampong F. Ostlund T. Hedge E. Laddusaw J. Alotaibi F. Elshaier Y.A.M.M. Halaweish F. Triazole-estradiol analogs induce apoptosis and inhibit EGFR and its downstream pathways in triple negative breast cancer. Molecules 2025 30 3 605 10.3390/molecules30030605 39942711
    [Google Scholar]
  30. Xiong N. Wu H. Yu Z. Advancements and challenges in triple-negative breast cancer: A comprehensive review of therapeutic and diagnostic strategies. Front Oncol 2024 14 1405491 10.3389/fonc.2024.1405491 38863622
    [Google Scholar]
  31. Hashemi M. Arani H.Z. Orouei S. Fallah S. Ghorbani A. Khaledabadi M. Kakavand A. Tavakolpournegari A. Saebfar H. Heidari H. Salimimoghadam S. Entezari M. Taheriazam A. Hushmandi K. EMT mechanism in breast cancer metastasis and drug resistance: Revisiting molecular interactions and biological functions. Biomed Pharmacother 2022 155 113774 10.1016/j.biopha.2022.113774 36271556
    [Google Scholar]
  32. Bartel D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009 136 2 215 233 10.1016/j.cell.2009.01.002 19167326
    [Google Scholar]
  33. Filipowicz W. Bhattacharyya S.N. Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat. Rev. Genet 2008 9 2 102 114 10.1038/nrg2290 18197166
    [Google Scholar]
  34. Iorio M.V. Croce C.M. microRNA involvement in human cancer. Carcinogenesis 2012 33 6 1126 1133 10.1093/carcin/bgs140 22491715
    [Google Scholar]
  35. Sabit H. Cevik E. Tombuloglu H. Abdel-Ghany S. Tombuloglu G. Esteller M. Triple negative breast cancer in the era of miRNA. Crit. Rev. Oncol. Hematol 2021 157 103196 10.1016/j.critrevonc.2020.103196 33307198
    [Google Scholar]
  36. Santana T.A.B.S. de Oliveira Passamai L. de Miranda F.S. Borin T.F. Borges G.F. Luiz W.B. Campos L.C.G. The Role of miRNAs in the prognosis of triple-negative breast cancer: A systematic review and meta-analysis. Diagnostics 2022 13 1 127 10.3390/diagnostics13010127 38201310
    [Google Scholar]
  37. Kozomara, A.; Birgaoanu, M.; Griffiths-Jones, S. miRBase: From microRNA sequences to function. Nucleic Acids Res. 2019 47 D1 D155 D162 10.1093/nar/gky1141 30423142
    [Google Scholar]
  38. Chen Z. Zhao Y. The mechanism underlying metastasis in triple-negative breast cancer: Focusing on the interplay between ferroptosis, epithelial-mesenchymal transition, and non-coding RNAs. Front Pharmacol 2025 15 1437022 10.3389/fphar.2024.1437022 39881868
    [Google Scholar]
  39. Parfenyev S.E. Daks A.A. Shuvalov O.Y. Fedorova O.A. Pestov N.B. Korneenko T.V. Barlev N.A. Dualistic role of ZEB1 and ZEB2 in tumor progression. Biol Direct 2025 20 1 32 10.1186/s13062‑025‑00604‑3 40114235
    [Google Scholar]
  40. Niu L. Bai Y. Yu M. Sun X. LINC00899 suppresses the progression of triple-negative breast cancer via the miRNA-425/PTEN axis and is a biomarker for neoadjuvant chemotherapy efficacy. J. Cancer 2025 16 5 1647 1655 10.7150/jca.100619 39991583
    [Google Scholar]
  41. Liu Y. Chen J. miR-425 suppresses EMT and the development of TNBC (triple-negative breast cancer) by targeting the TGF-β 1/SMAD 3 signaling pathway. RSC Advances 2019 9 1 151 165 10.1039/C8RA08872A 35521597
    [Google Scholar]
  42. Valcourt D.M. Day E.S. Dual regulation of miR-34a and notch signaling in triple-negative breast cancer by antibody/miRNA nanocarriers. Mol. Ther. Nucleic. Acids 2020 21 290 298 10.1016/j.omtn.2020.06.003 32622330
    [Google Scholar]
  43. Parfenyev S. Singh A. Fedorova O. Daks A. Kulshreshtha R. Barlev N.A. Interplay between p53 and non-coding RNAs in the regulation of EMT in breast cancer. Cell Death Dis 2021 12 1 17 10.1038/s41419‑020‑03327‑7 33414456
    [Google Scholar]
  44. Garinet S. Didelot A. Denize T. Perrier A. Beinse G. Leclere J.B. Oudart J.B. Gibault L. Badoual C. Le Pimpec-Barthes F. Laurent-Puig P. Legras A. Blons H. Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC. Br. J. Cancer 2021 125 11 1544 1551 10.1038/s41416‑021‑01568‑7 34642464
    [Google Scholar]
  45. Berti F.C.B. Tofolo M.V. Nunes-Souza E. Marchi R. Okano L.M. Ruthes M. Rosolen D. Malheiros D. Fonseca A.S. Cavalli L.R. Extracellular vesicles-associated miRNAs in triple-negative breast cancer: From tumor biology to clinical relevance. Life Sci 2024 336 122332 10.1016/j.lfs.2023.122332 38070862
    [Google Scholar]
  46. Jain P. Corbo S. Mohammad K. Sahoo S. Ranganathan S. George J.T. Levine H. Taube J. Toneff M. Jolly M.K. Epigenetic memory acquired during long-term EMT induction governs the recovery to the epithelial state. J. R. Soc. Interface 2023 20 198 20220627 10.1098/rsif.2022.0627 36628532
    [Google Scholar]
  47. Funato N. Yanagisawa H. TBX1 targets the miR-200–ZEB2 axis to induce epithelial differentiation and inhibit stem cell properties. Sci. Rep 2022 12 1 20188 10.1038/s41598‑022‑24604‑9 36418889
    [Google Scholar]
  48. Mitobe Y. Ikeda K. Sato W. Kodama Y. Naito M. Gotoh N. Miyata K. Kataoka K. Sasaki H. Horie-Inoue K. Inoue S. Proliferation-associated long noncoding RNA, TMPO-AS1 , is a potential therapeutic target for triple-negative breast cancer. Cancer Sci 2020 111 7 2440 2450 10.1111/cas.14498 32437068
    [Google Scholar]
  49. Li J. Ma M. Yang X. Zhang M. Luo J. Zhou H. Huang N. Xiao F. Lai B. Lv W. Zhang N. Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab. Mol Cancer 2020 19 1 142 10.1186/s12943‑020‑01259‑6 32917240
    [Google Scholar]
  50. Wu L. Huang S. Tian W. Liu P. Xie Y. Qiu Y. Li X. Tang Y. Zheng S. Sun Y. Tang H. Du W. Tan W. Xie X. PIWI-interacting RNA-YBX1 inhibits proliferation and metastasis by the MAPK signaling pathway via YBX1 in triple-negative breast cancer. Cell Death Discov 2024 10 1 7 10.1038/s41420‑023‑01771‑w 38182573
    [Google Scholar]
  51. Lai Y.W. Hsu W.J. Lee W.Y. Chen C.H. Tsai Y.H. Dai J.Z. Yang C.C. Lin C.W. Prognostic value of a glycolytic signature and its regulation by Y-box-binding protein 1 in triple-negative breast cancer. Cells 2021 10 8 1890 10.3390/cells10081890 34440660
    [Google Scholar]
  52. Seok H. Lee H. Jang E.S. Chi S.W. Evaluation and control of miRNA-like off-target repression for RNA interference. Cell Mol Life Sci 2018 75 5 797 814 10.1007/s00018‑017‑2656‑0 28905147
    [Google Scholar]
  53. Herkt M. Thum T. Pharmacokinetics and proceedings in clinical application of nucleic acid therapeutics. Mol Ther 2021 29 2 521 539 10.1016/j.ymthe.2020.11.008 33188937
    [Google Scholar]
  54. Debacker A.J. Voutila J. Catley M. Blakey D. Habib N. Delivery of oligonucleotides to the liver with GalNAc: From research to registered therapeutic drug. Mol Ther 2020 28 8 1759 1771 10.1016/j.ymthe.2020.06.015 32592692
    [Google Scholar]
  55. Kim T. Croce C.M. MicroRNA: Trends in clinical trials of cancer diagnosis and therapy strategies. Exp. Mol. Med 2023 55 7 1314 1321 10.1038/s12276‑023‑01050‑9 37430087
    [Google Scholar]
  56. Sun X. Setrerrahmane S. Li C. Hu J. Xu H. Nucleic acid drugs: Recent progress and future perspectives. Signal Transduct Target Ther 2024 9 1 316 10.1038/s41392‑024‑02035‑4 39609384
    [Google Scholar]
  57. Kauppinen S. Vester B. Wengel J. Locked nucleic acid (LNA): High affinity targeting of RNA for diagnostics and therapeutics. Drug Discov Today Technol 2005 2 3 287 290 10.1016/j.ddtec.2005.08.012 24981949
    [Google Scholar]
  58. Baker Y.R. Thorpe C. Chen J. Poller L.M. Cox L. Kumar P. Lim W.F. Lie L. McClorey G. Epple S. Singleton D. McDonough M.A. Hardwick J.S. Christensen K.E. Wood M.J.A. Hall J.P. El-Sagheer A.H. Brown T. An LNA-amide modification that enhances the cell uptake and activity of phosphorothioate exon-skipping oligonucleotides. Nat Commun 2022 13 1 4036 10.1038/s41467‑022‑31636‑2 35821218
    [Google Scholar]
  59. Carlesso A. Hörberg J. Deganutti G. Reymer A. Matsson P. Structural dynamics of therapeutic nucleic acids with phosphorothioate backbone modifications. NAR Genom. Bioinform 2024 6 2 lqae058 10.1093/nargab/lqae058 38800826
    [Google Scholar]
  60. Rupaimoole R. Slack F.J. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov 2017 16 3 203 222 10.1038/nrd.2016.246 28209991
    [Google Scholar]
  61. Moraes F.C. Pichon C. Letourneur D. Chaubet F. miRNA delivery by nanosystems: State of the art and perspectives. Pharmaceutics 2021 13 11 1901 10.3390/pharmaceutics13111901 34834316
    [Google Scholar]
  62. Scheideler Marcel Lipid nanocarriers for microRNA delivery. Chem. Phys. Lipids 2020 226 104837 10.1016/j.chemphyslip.2019.104837
    [Google Scholar]
  63. Chen H. Wang L. Zeng X. Schwarz H. Nanda H.S. Peng X. Zhou Y. Exosomes, a new star for targeted delivery. Front. Cell. Dev. Biol 2021 9 751079 10.3389/fcell.2021.751079 34692704
    [Google Scholar]
  64. Tzng E. Bayardo N. Yang P.C. Current challenges surrounding exosome treatments. Extra cell Vesicle 2023 2 100023 10.1016/j.vesic.2023.100023 40027080
    [Google Scholar]
  65. Tang J. Jia X. Li Q. Cui Z. Liang A. Ke B. Yang D. Yao C. A DNA-based hydrogel for exosome separation and biomedical applications. Proc. Natl. Acad. Sci. USA 2023 120 28 e2303822120 10.1073/pnas.2303822120 37399419
    [Google Scholar]
  66. Yan Y. Liu X.Y. Lu A. Wang X.Y. Jiang L.X. Wang J.C. Non-viral vectors for RNA delivery. J. Control Release 2022 342 241 279 10.1016/j.jconrel.2022.01.008 35016918
    [Google Scholar]
  67. Lee S.H. Ng C.X. Wong S.R. Chong P.P. MiRNAs overexpression and their role in breast cancer: implications for cancer therapeutics. Curr. Drug. Targets 2023 24 6 484 508 10.2174/1389450124666230329123409 36999414
    [Google Scholar]
  68. Hong D.S. Kang Y.K. Borad M. Sachdev J. Ejadi S. Lim H.Y. Brenner A.J. Park K. Lee J.L. Kim T.Y. Shin S. Becerra C.R. Falchook G. Stoudemire J. Martin D. Kelnar K. Peltier H. Bonato V. Bader A.G. Smith S. Kim S. O’Neill V. Beg M.S. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br. J. Cancer 2020 122 11 1630 1637 10.1038/s41416‑020‑0802‑1 32238921
    [Google Scholar]
  69. Esau C. Davis S. Murray S.F. Yu X.X. Pandey S.K. Pear M. Watts L. Booten S.L. Graham M. McKay R. Subramaniam A. Propp S. Lollo B.A. Freier S. Bennett C.F. Bhanot S. Monia B.P. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006 3 2 87 98 10.1016/j.cmet.2006.01.005 16459310
    [Google Scholar]
  70. Khan A.A. Betel D. Miller M.L. Sander C. Leslie C.S. Marks D.S. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol 2009 27 6 549 555 10.1038/nbt.1543 19465925
    [Google Scholar]
  71. Lindsay M.A. microRNAs and the immune response. Trends Immunol 2008 29 7 343 351 10.1016/j.it.2008.04.004 18515182
    [Google Scholar]
  72. Diener C. Keller A. Meese E. Emerging concepts of miRNA therapeutics: From cells to clinic. Trends Genet 2022 38 6 613 626 10.1016/j.tig.2022.02.006 35303998
    [Google Scholar]
  73. Tian H. Cheng L. Liang Y. Lei H. Qin M. Li X. Ren Y. MicroRNA therapeutic delivery strategies: A review. J. Drug. Deliv. Sci. Technol 2024 93 105430 10.1016/j.jddst.2024.105430
    [Google Scholar]
  74. Seyhan A.A. Trials and tribulations of MicroRNA therapeutics. Int. J. Mol. Sci 2024 25 3 1469 10.3390/ijms25031469 38338746
    [Google Scholar]
  75. Kumamoto K. Spillare E.A. Fujita K. Horikawa I. Yamashita T. Appella E. Nagashima M. Takenoshita S. Yokota J. Harris C.C. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 2008 68 9 3193 3203 10.1158/0008‑5472.CAN‑07‑2780 18451145
    [Google Scholar]
  76. Barlev N.A. Sayan B.S. Candi E. Okorokov A.L. The microRNA and p53 families join forces against cancer. Cell Death Differ 2010 17 2 373 375 10.1038/cdd.2009.73 20062068
    [Google Scholar]
  77. Qattan A. Novel miRNA targets and therapies in the triple-negative breast cancer microenvironment: An emerging hope for a challenging disease. Int. J. Mol. Sci 2020 21 23 8905 10.3390/ijms21238905 33255471
    [Google Scholar]
  78. He P. Tang H. Zheng Y. Xiong Y. Cheng H. Li J. Zhang Y. Liu G. Advances in nanomedicines for lymphatic imaging and therapy. J. Nanobiotechnology 2023 21 1 292 10.1186/s12951‑023‑02022‑x 37620846
    [Google Scholar]
  79. Cohen M.S. Forrest M.L. Lymphatic drug delivery: Therapy, imaging and nanotechnology. Adv. Drug. Deliv. Rev 2011 63 10-11 865 866 10.1016/j.addr.2011.05.013 21669240
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673382509250801061216
Loading
Epithelial to Mesenchymal Transition as a Therapeutic Target for MicroRNAs in Triple Negative Breast Cancer
Bentham Science Publishers ; https://doi.org/10.2174/0109298673382509250801061216
/content/journals/cmc/10.2174/0109298673382509250801061216
/content/journals/cmc/10.2174/0109298673382509250801061216
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: Zeb1 ; EMT ; Breast cancer ; drug resistance ; miRNA ; p53 ; TNBC

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test